4DMT Appoints Kristian Humer As CFO
(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a biotechnology company, Monday announced that it has appointed Kristian Humer as its new chief financial officer.
Humer will be replacing Uneek Mehra, who stepped down from his role in July this year.
Humer has more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking and was the Managing Director in Citi's Healthcare Investment Banking Group. He was also the finance chief of publicly traded companies including Foghorn Therapeutics, Inc. and Viridian Therapeutics, Inc.
On Friday, FDMT shares closed at $10.79, up 4.96% on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.